Cd80 - CD80 antigen Gene
Also Known as B71; Ly53; TSA1; Cd28l; Ly-53; MIC17
Species: Mus musculus
Gene Type: protein coding
Gene ID: 12519
Summary
Predicted to enable coreceptor activity. Acts upstream of or within T cell costimulation; cellular response to lipopolysaccharide; and positive regulation of alpha-beta T cell proliferation. Located in external side of plasma membrane. Is expressed in heart ventricle and skin. Human ortholog(s) of this gene implicated in type 1 diabetes mellitus. Orthologous to human CD80 (CD80 molecule). [provided by Alliance of Genome Resources, Apr 2022]
Cd80 Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_001359898.1 | NP_001346827.1 | T-lymphocyte activation antigen CD80 precursor |
| NM_009855.2 | NP_033985.3 | T-lymphocyte activation antigen CD80 precursor |
| Molecular Function GO Annotation | Evidence | Références | Source |
|---|---|---|---|
| enables protein binding |
IPI
IPI: Inferred from physical interaction
|
1385153 | MGI |
| Biological Process GO Annotation | Evidence | Références | Source |
|---|---|---|---|
| acts upstream of or within T cell costimulation |
IDA
IDA: Inferred from direct assay
|
1385153 | MGI |
| acts upstream of or within cellular response to lipopolysaccharide |
IDA
IDA: Inferred from direct assay
|
19047410 | MGI |
| acts upstream of or within positive regulation of T cell proliferation |
IGI
IGI: Inferred from genetic interaction
|
23793062 | MGI |
| acts upstream of or within positive regulation of alpha-beta T cell proliferation |
IDA
IDA: Inferred from direct assay
|
1385153 | MGI |
| Cellular Component GO Annotation | Evidence | Références | Source |
|---|---|---|---|
| located in external side of plasma membrane |
IDA
IDA: Inferred from direct assay
|
1385153 | MGI |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
T-lymphocyte activation antigen CD80 |
|
Recombinant Cd80 Proteins
| Cat. No. | Nom du produit | Accession | Pureté |
|---|---|---|---|
| HY-P7632 | B7-1/CD80 Protein, Mouse (HEK293, Fc) | Q00609 (V38-K245) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P7633 | B7-1/CD80 Protein, Mouse (HEK293, His) | Q00609 (V38-N246) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P77523 | B7-1/CD80 Protein, Mouse (Biotinylated, HEK293, His) | Q00609 (V38-K245) | ≥ 95%, as determined by reducing SDS-PAGE. |
Cd80 Anticorps
| Cat. No. | Nom du produit | Application | Reactivity |
|---|---|---|---|
| HY-P810805 | CD80 Antibody (YA10048) | ICC/IF, FC | Mouse |
| HY-P83711M | Armenian Hamster Anti-Mouse CD80 Antibody (PE) (YA3448) | FC | Mouse |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Inhibitory Antibodies
(1)
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9919 | Durvalumab | Inhibitor | 99.60% | Unkown |
Clinical Phase
Bioactive Molecules
(1)
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Phase
|
|---|---|---|---|---|
| HY-148511 | Vidutolimod | 93.85% | Phase 3 |
Inhibitory Antibodies
(9)
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Phase
|
|---|---|---|---|---|
| HY-P99293 | Galiximab | 99.23% | Phase 3 | |
| HY-P9996 | Reozalimab | Inhibitor | 99.90% | Phase 2 |
| HY-P99809 | Quavonlimab | Inhibitor | ≥99.0% | Phase 2 |
| HY-P990992 | Efzilonkofusp alfa | / | Phase 2 | |
| HY-P991566 | KD6001 | Inhibitor | / | Phase 2 |
| HY-P99844 | Davoceticept | 99.9% | Phase 1 | |
| HY-P99709 | Lodapolimab | Inhibitor | 99.71% | Phase 1 |
| HY-P991952 | ADU-1604 | Inhibitor | / | Phase 1 |
| HY-P991961 | REGN4659 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(18)
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Rare Diseases
|
|---|---|---|---|---|
| HY-150749A | ODN D-SL03 sodium | 98.57% | Unkown | |
| HY-W722277A | LCC-12 formate | Inhibitor | 99.90% | Unkown |
| HY-100891 | CD80-IN-3 | 98.02% | Unkown | |
| HY-103048A | PD-1/PD-L1-IN 3 TFA | Inhibitor | 99.34% | Unkown |
| HY-150749 | ODN D-SL03 | Inducer | 99.82% | Unkown |
| HY-N10116A | Calamenene | / | Unkown | |
| HY-103048 | PD-1/PD-L1-IN 3 | Inhibitor | / | Unkown |
| HY-160227 | ORN 06 | Activator | / | Unkown |
| HY-161833 | HSP90-IN-31 | Inhibitor | / | Unkown |
| HY-169819 | Calcium influx inducer compound 634 | / | Unkown | |
| HY-171883 | BI-5756 | / | Unkown | |
| HY-176265 | DDS5 | Inhibitor | / | Unkown |
| HY-178945 | KOR agonist 7 | / | Unkown | |
| HY-RS02269 | CD80 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-168384 | M04 | / | Unkown | |
| HY-184441 | CD28-IN-4 | Inhibitor | / | Unkown |
| HY-RS16921 | Cd80 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23364 | Cd80 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Inhibitory Antibodies
(12)
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9919A | Durvalumab (anti-PD-L1) | Inhibitor | 99.0% | Unkown |
| HY-P991907 | Anti-CD80 Antibody (TKMF5) | 96.92% | Unkown | |
| HY-P990127 | Anti-Mouse CD80/B7-1 Antibody (RM80) | Inhibitor | 95% | Unkown |
| HY-P990128 | Anti-Rat CD80/B7-1 Antibody (3H5) | Inhibitor | / | Unkown |
| HY-P990986 | Efdelikofusp alfa | / | Unkown | |
| HY-P991826 | Anti-Mouse CD80 Antibody (16-10A1) | Inhibitor | / | Unkown |
| HY-P991831 | Anti-Mouse CD80/B7-1 Antibody (1G10) | Inhibitor | / | Unkown |
| HY-P991918 | KHK2840 | Agonist | / | Unkown |
| HY-P992062 | Anti-Mouse CD80 Antibody (TKMG48) | Agonist | / | Unkown |
| HY-P992408 | MEDI-5083 | / | Unkown | |
| HY-P992511 | CS2009 | Inhibitor | / | Unkown |
| HY-P991958 | GIGA-564 | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service